Sugi Predict

Sugi Predict / Compounds / SCHEMBL537829

SCHEMBL537829

SCHEMBL537829

CCOC(=O)c1c(Cl)nc(SC)nc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.48
▸ LMNA P02545 4/20 0.48
▸ TSHR P16473 3/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ PDE4D Q08499 1/20 0.43
▸ HPGD P15428 4/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ PKM P14618 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ GAA P10253 2/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31207902 0.94 LMNA (0.44) MAPTLMNATSHRNPSR1MAPK1
SCHEMBL1298575 0.94 LMNA (0.44) MAPTLMNATSHRNPSR1MAPK1
SCHEMBL31207901 0.94 LMNA (0.44) MAPTLMNATSHRNPSR1MAPK1
SCHEMBL9124409 0.92 MAPT (0.43) MAPTLMNATSHRNPSR1MAPK1
SCHEMBL22573664 0.91 KDM4E (0.49) MAPTLMNATSHRNPSR1MAPK1
SCHEMBL25366832 0.89 ALDH1A1 (0.41) MAPTLMNATSHRNPSR1MAPK1
SCHEMBL30558073 0.89 ALDH1A1 (0.41) MAPTLMNATSHRNPSR1MAPK1
SCHEMBL14407169 0.88 MAPT (0.41) MAPTLMNATSHRNPSR1MAPK1
SCHEMBL30926036 0.88 MAPT (0.47) MAPTLMNATSHRNPSR1MAPK1
SCHEMBL25366055 0.88 MAPT (0.41) MAPTLMNATSHRNPSR1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637461-B2 Compounds for the activation of AMPK PFIZER INC. (US) 2026-05-26 — — US disclosed
EP-4626888-A1 COMPOUNDS Redx Pharma Limited (GB) 2025-10-08 — — EP disclosed
US-20250129084-A1 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-04-24 — — US disclosed
EP-4486454-A1 COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-01-08 — — EP disclosed
WO-2024115890-A1 COMPOUNDS REDX PHARMA PLC (GB) 2024-06-06 — — WO disclosed
US-20240182468-A1 COMPOUNDS FOR THE ACTIVATION OF AMPK PFIZER (US) 2024-06-06 — — US disclosed
WO-2024084390-A1 COMPOUNDS FOR THE ACTIVATION OF AMPK PFIZER INC. (US) 2024-04-25 — — WO disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 — — US disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 — — US disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 — — US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 — — US disclosed
EP-2414359-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ArQule, Inc. (US) 2012-02-08 — — EP disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US disclosed
WO-2010114905-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-10-07 — — WO disclosed
WO-2010114905-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-10-07 — — WO disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 — — US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 — — US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 — — US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182468-A1 COMPOUNDS FOR THE ACTIVATION OF AMPK PRKAG1, PRKAG2, PRKAB1 MAPT 3041/4885LMNA 3011/4885TSHR 3141/4885
US-20250129084-A1 Compounds CFTR, TBCA, TBCD MAPT 217/4885LMNA 3158/4885TSHR 3455/4885
US-12637461-B2 Compounds for the activation of AMPK PRKAG1, PRKAB1, PRKAA1 MAPT 4344/4885LMNA 2111/4885TSHR 794/4885
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 MAPT 2947/4885LMNA 2815/4885TSHR 3555/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 MAPT 1608/4885LMNA 3483/4885TSHR 283/4885
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF KRAS, NRAS, HRAS MAPT 4801/4885LMNA 3767/4885TSHR 3862/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 MAPT 1608/4885LMNA 3483/4885TSHR 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.